Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

IQVIA Holdings, Inc. Common Stock (NY:IQV)

145.93 -7.08 (-4.63%)
Streaming Delayed Price Updated: 3:28 PM EDT, Apr 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about IQVIA Holdings, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
What's going on in today's session: S&P500 gap up and gap down stocks
Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest... 
Via StockStory
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers. 
Via StockStory
Earnings Scheduled For February 6, 2025
Via Benzinga
Analyst Expectations For IQVIA Hldgs's Future
Via Benzinga
How Is The Market Feeling About IQVIA Hldgs?
Via Benzinga
(IQV) - Analyzing IQVIA Hldgs's Short Interest
Via Benzinga
Peering Into IQVIA Hldgs's Recent Short Interest
Via Benzinga
3 Reasons IQV is Risky and 1 Stock to Buy Instead
IQVIA’s stock price has taken a beating over the past six months, shedding 22.2% of its value and falling to $190.42 per share. This may have investors wondering how to approach the situation. 
Via StockStory
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. 
Via StockStory
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and... 
Via StockStory
Looking Into IQVIA Hldgs's Recent Short Interest
Via Benzinga
Peeling Back The Layers: Exploring IQVIA Hldgs Through Analyst Insights
Via Benzinga
How Is The Market Feeling About IQVIA Hldgs?
Via Benzinga
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor
Loeb's Third Point LLC restructured their portfolio in last quarter of 2024. They decreased stake in Danaher Corp. and acquired stake in Thermo Fisher. 
Via Benzinga
Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting earnings tomorrow before the bell. Here’s what investors should know. 
Via StockStory
West Pharmaceutical Services (WST) Q4 Earnings Report Preview: What To Look For
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours. Here’s what to expect. 
Via StockStory
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged... 
Via Benzinga
Topics Stocks
Exposures US Equities
IQVIA Delivers Solid Q4 Growth Despite 'Choppy' Market Conditions
IQVIA reaffirms its 2025 outlook, projecting up to $16.13 billion in revenue and EPS of $11.70-$12.10. Strong TAS growth and solid R&DS bookings fuel confidence. 
Via Benzinga
Gapping S&P500 stocks in Thursday's session
Stay updated with the S&P500 gap up and gap down stocks on Thursday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Wondering what's happening in today's S&P500 pre-market session?
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
IQVIA (NYSE:IQV) Exceeds Q4 Expectations, Stock Soars
Clinical research company IQVIA (NYSE: IQV) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.3% year on year to $3.96 billion. On the other hand, the company’s full-year revenue... 
Via StockStory
IQVIA (IQV) Q4 Earnings Report Preview: What To Look For
Clinical research company IQVIA (NYSE: IQV) will be announcing earnings results tomorrow before market hours. Here’s what to look for. 
Via StockStory
Nvidia Eyes $1 Billion In Healthcare AI Revenue: Is This The Next Growth Frontier?
Nvidia is making an ambitious leap into leveraging AI and accelerated computing to transform healthcare solutions. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Elliott Investment Management Adds To Southwest, Western Digital, Etsy, Match Group; Trims BILL Holdings, Seadrill, BlackLine, NRG Energy In Q3
Elliott Investment Management was busy in the third quarter. According to a new 13-F filing with the SEC, the activist made several portfolio moves, with multiple new positions focused around travel... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age group and reducing demand by two-thirds compared to last year. 
Via Benzinga
Four Stocks To Watch This Week - Tuesday, Oct. 01
A flat week that was anticipated, one notable event was China's stimulus package announcement, which sent China-related stocks soaring. Most of these stocks surged without prior consolidations/warning... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.